Bridging the Gap Between Basic Research and Industrial Application
Professor Dr Pierre Jacobs, KU Leuven (Belgium), has received the BASF-DECHEMA Alwin Mittasch Special Prize for his research into materials and their use as process catalysts. The award, which comes with €10,000 in prize money, was presented at the “Future Loves History — 100 Years of Ammonia Synthesis” scientific symposium at BASF in Ludwigshafen.
“Professor Jacobs has succeeded in a special way in spanning the bridge between basic research and industrial application,” said Professor Rainer Diercks, President Petrochemicals BASF and Chairman of DECHEMA. Initially focusing on zeolites and their use in catalysis, Pierre Jacobs gradually expanded his research activities to include other heterogeneous and homogeneous catalytic processes. Many of his research insights are now in industrial use. These include synthesis of g-butyrolactone from maleic acid anhydride, an important step in the manufacture of anti-dementia drugs, and side chain alkylation of alkyl-substituted anthraquinones, an intermediate step in industrial hydrogen peroxide production. His research areas also include catalytic processing of biomass.
DECHEMA confers the Alwin Mittasch Prize usually every 3 years. This year BASF sponsored a special prize to mark the 100th anniversary of the commissioning of the first ammonia plant in September 1913. “Without the enormous efforts of catalyst research, the Haber-Bosch process for ammonia production would never have been transferred to industrial scale and this world would be a different place,” Dr Peter Schuhmacher, President Process Research and Chemical Engineering said. “For that reason, it was a matter of great importance to us to present the award to someone who is continuing Alwin Mittasch’s legacy.”
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance